Connor, Clark & Lunn Investment Management (CC&L)’s Protagonist Therapeutics PTGX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.57M	Buy	29,161 +1,901	+7%	+$199K	0.01%	828
2026 Q1	$2.87M	Buy	27,260 +13,990	+105%	+$1.24M	0.01%	851
2025 Q4	$1.16M	Buy	+13,270	New	+$1.09M	﹤0.01%	1089
2024 Q3	–	Sell	-82,791	Closed	-$2.87M	–	1604
2024 Q2	$2.87M	Sell	82,791 -10,395	-11%	-$304K	0.01%	560
2024 Q1	$2.7M	Sell	93,186 -14,356	-13%	-$391K	0.01%	593
2023 Q4	$2.47M	Sell	107,542 -31,952	-23%	-$559K	0.01%	616
2023 Q3	$2.33M	Sell	139,494 -23,931	-15%	-$464K	0.01%	576
2023 Q2	$4.51M	Buy	163,425 +41,401	+34%	+$1.04M	0.02%	419
2023 Q1	$2.81M	Sell	122,024 -72,680	-37%	-$1.22M	0.02%	486
2022 Q4	$2.12M	Buy	194,704 +3,511	+2%	+$29.6K	0.01%	526
2022 Q3	$1.61M	Buy	+191,193	New	+$1.81M	0.01%	539
2020 Q3	–	Sell	-28,598	Closed	-$505K	–	1085
2020 Q2	$505K	Buy	+28,598	New	+$359K	﹤0.01%	755

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PTGX Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Protagonist Therapeutics (PTGX) stake by 7% in Q2 2026, buying an estimated $199K and bringing the position to 29,161 shares worth $3.57M. The position accounts for 0.01% of the portfolio, ranked #828.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PTGX in Q2 2020 and has held it in 12 quarters since. The position peaked at $4.51M in Q2 2023. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 29,161 shares of Protagonist Therapeutics worth $3.57M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 1,901 Protagonist Therapeutics shares in Q2 2026, an estimated $199K.
Protagonist Therapeutics made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #828 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Protagonist Therapeutics in Q2 2020 and has held it in 12 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Protagonist Therapeutics position peaked at $4.51M in Q2 2023.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.